Blood Center/Blood Hospital-Based Donor Center

(P-BB-1) Factors Influencing White Blood Cell (WBC) Mobilization in Healthy Granulocyte Donors.

(P-BB-2) 12-Hour Hold in Large Volume Delayed Sampling of Platelet Products: Is it Needed?

(P-BB-3) A case of Brucella abortus RB51 positive platelet unit culture

(P-BB-4) A Comparison of Warm verses Cold Market Prospecting for Recruiting Participants to Special Collections and Clinical Research at Community Blood Banks

(P-BB-5) A New Thermoregulated Container System for Cold Processing of Whole Blood Donations in Extreme Climate Conditions

(P-BB-6) A Practical Option for Platelet Shortages: A Warm to Cold Storage Converted Apheresis Platelet Program During the COVID-19 Pandemic

(P-BB-7) A Survey of Blood Donors’ Response on the Combination of Blood Donor Registration and Hemoglobin Testing Stations

(P-BB-8) A Survey to Understand C1 Esterase Inhibitor Distribution Patterns and Use in Canada

(P-BB-9) Accuracy of Non-invasive Hemoglobin Assessment In Whole Blood and Apheresis Donors

(P-BB-10) Alternative Wash Procedure Implementation During COVID Pandemic Supply Chain Disruptions

(P-BB-11) Analysis of Donor Moderate and Severe Vasovagal Reactions During Donation on the Alyx Collection Device

(P-BB-12) Analysis of Donors Deferred for vCJD Risks and Impact of Revised FDA Guidance

(P-BB-13) Analysis of impact of COVID-19 pandemic on the activity of plateletapheresis:a study of 11 blood centers in China

(P-BB-14) Analysis of the Benefit of Implementing a Helipad for Rotation and Resupply of Low Titer O Whole Blood to Prehospital Entities

(P-BB-15) Applying Qualified Metrics to Monitor Performance in the Collection of Apheresis Double Red Blood Cells

(P-BB-16) Assessment of Point-of-Care, Rapid Diagnostic Tests for Transfusion Transmissible Infections for a Walking Blood Bank

(P-BB-17) Biochemical Parameters At Day 7 Of Storage Of Pathogen Reduced (UVA/Amotosalen) And Conventional Platelets In Additive Solution With Or Without Irradiation.

(P-BB-18) Blood donor questionnaires and infectious disease screening in Latin American countries

(P-BB-19) Building The Bridge for Prehospital Blood Transfusion: a Standardized Approach from a Blood Center

(P-BB-20) Can We Consider Platelets in Platelet Additive Solution as “High Titre Negative” for Anti-A/B?

(P-BB-21) Choosing the Best Source of WBCs: Apheresis LRS Chambers versus Buffy Coat Products

(P-BB-22) CLIA-Waived Hematology Analyzer Quandary: What to With **** Results in Platelet Donor Qualification

(P-BB-23) Clinical and Epidemiological Characteristics of Arbovirus Infections in Blood Donors

(P-BB-24) Comparing Cryoprecipitate Fibrinogen Content by Plasma Thawing Technique

(P-BB-25) Comparison of Cryoprecipitated AHF Manufactured from FFP and PF24

(P-BB-26) Comparison of Quality Parameters from Whole Blood, Control Units Processed in a Mexican Blood Bank Center with Automated and Semi-Automated Processing Systems

(P-BB-27) Day 6 and 7 Platelets are Not Associated with Increased Transfusion Reaction Rates – A Multicenter Analysis

(P-BB-28) Determining the Validity of IgA Deficient Product Requests Submitted to the American Rare Donor Program from 2018 to 2022

(P-BB-29) Donor Re-Entry Following Deferral for False Reactive Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus Markers.

(P-BB-30) Donor Return Behavior in South Africa: A Comparison between Mobile and Fixed Site Blood Drives

(P-BB-31) Donors on Testosterone Replacement Therapy have Elevated Testosterone Concentrations in Plasma and can be Mitigated with Pathogen Reduction Technology

(P-BB-32) Effect of COVID-19 Precautions on Donor Adverse Events (DAE) in the Apheresis Donor Population at a Hospital-Based Donor Center

(P-BB-33) Effectiveness and Efficiency of Processing Low Volume Red Blood Cells (RBC) In Blood Services Group (BSG), Singapore

(P-BB-34) Establishing a Platelet Apheresis Unit in Zambia a Resource Restricted Country

(P-BB-35) Evaluating Thrombocytosis in Apheresis Platelet Donors

(P-BB-36) Evaluation of the Usability of an Automated Whole Blood Processing System

(P-BB-37) Expansion of Low Titer O Whole Blood Donor Eligibility

(P-BB-38) Exposure of Cryopreserved Red Cell Concentrates to Real-World Transient Warming Events Has a Negligible Impact on Quality

(P-BB-39) Frequency of vasovagal reactions with large volume plasma donations in Canada

(P-BB-40) Hospital and Blood Center Collaboration to Improve Platelet Delivery Efficiency: Increased Inventory Without Increased Wastage

(P-BB-41) Humoral Response to COVID-19 Vaccination in Frequent Plasmapheresis Donors

(P-BB-42) IgA-deficient Donors – Screening Process and Data From Three US Centers

(P-BB-43) Impact of irradiation on quality of conventional and pathogen reduced platelets with 5-day storage

(P-BB-44) Impact of Label Orientation on in vitro Parameters of Platelets During Storage

(P-BB-45) Implementing sexual behavior-based screening: Staff training has never been more important

(P-BB-46) Improvement of Phlebotomy Success Identified by Utilizing Green Belt Tools and Vein Viability Training

(P-BB-47) Improving Blood Availability in Blood Deserts of LMICs through Implementation of Civilian Walking Blood Banks: Conclusions from an International Working Group.

(P-BB-48) Improving Platelet Collection Efficiency with Data Management

(P-BB-49) Increase in bacterially contaminated platelets with the implementation of LVDS

(P-BB-50) Increased Unconfirmed Peak Syphilis Repeat Reactive Rates in Canadian Blood Doors in the COVID-19 Pandemic Period Compared to the Pre-pandemic Period.

(P-BB-51) Increasing Blood Diversity: How Blood Center Websites Tackle Critical Blood Shortages for Sickle Cell Patients through Recruitment of African-American Donors

(P-BB-52) Interim Platelet Units Prepared from Automated WB Processing Meet In Vitro Acceptance Criteria and are Less Activated than Manually Prepared PRP Platelets

(P-BB-53) Is Average Donor Platelet Count Equivalent to Manufacturer's Recommended Average?

(P-BB-54) Loss of Consciousness Reactions in Donors Reporting Current or Past History of Cardiovascular Disease

(P-BB-55) Lower Cost of Monitoring Leukocyte Reduction QC of Platelets With No Sampling

(P-BB-56) Mitigation Steps to Reduce Platelet Discard Rates due to Aggregates

(P-BB-57) Moving Away from Single Platelet Collections: A Culture Change through Education and Communication

(P-BB-58) Nucleocapsid Antibody Boosting to Identify SARS-CoV-2 Reinfections among United States Blood Donors

(P-BB-59) Optimizing donor malaria management in Australia using a risk and cost effectiveness analysis

(P-BB-60) Platelet Dose in LVDS48 Apheresis Platelets, Leukocytes Reduced

(P-BB-61) Polymicrobial contamination of Platelets involving Acinetobacter spp., Staphylococcus saprophyticus, or Leclercia adecarboxylata

(P-BB-62) Postcollection processing of packed RBCs from pig

(P-BB-63) Preliminary Feasibility of an Artificial Intelligence (AI) Smartphone-based ABO-RhD Blood Typing Kit to Reach New Blood Donors

(P-BB-64) Prevalence of HLA sensitization in men who have sex with men and correlation with sexual practices

(P-BB-65) Radiofrequency Identification Tracking System Significantly Improves Blood Bank Inventory Management and Decreases Staff Work Effort

(P-BB-66) Recruiting First Time Donors into Automated Double Red Cell Collections: A Revenue Diversification & Inventory Management Strategy From a Community Blood Center

(P-BB-67) Recruitment of Cannabis Consumers as Blood Donors to Improve Blood Availability.

(P-BB-68) Reference Ranges for Complete Blood Count in Platelet Apheresis Donors at an Intermediate Altitude

(P-BB-69) Serving Patients Through Efficient New Platelets Program

(P-BB-70) Simultaneous Detection of Dengue, Zika and Chikungunya Viruses in Blood Donors During Two Different Epidemiological Periods in Colombia

(P-BB-71) Single Transient Warming Events do not Affect the Quality of Cryopreserved Red Cell Concentrates

(P-BB-72) Survival of Plasmodium falciparum parasites in human plasma under different storage temperatures

(P-BB-73) The American Rare Donor Program and Exports of Rare Blood Products, 2008-2022

(P-BB-74) The Innovative Exploration of RFID Technology in Blood Center Processes

(P-BB-75) The Science…or Not Behind Deferrals of Blood Donors With a History of Cancer

(P-BB-76) The Use of Mixed Reality Technology within the Donor Collection Experience

(P-BB-77) Validation of a Small-Scale Red Blood Cell Cryopreservation Method

(P-BB-78) WhatsApp Intervention to Increase Repeat Blood Donation in Ghana: A Pilot Randomized Controlled Trial - BLOODSAFE Ghana Study

(P-BB-79) Will Donors Return After Deferral: One Center’s Experience with Reinstatement After New FDA Guidance on Creutzfeldt-Jakob Disease